Although several studies have demonstrated the efficacy of large volume leukapheresis (LVL) to yield high numbers of peripheral blood progenitor cells (PBPC), the mechanisms of stem cell release into circulation and the postulated phenomenon of PBPC recruitment during apheresis have not been investigated in detail. Therefore, we analyzed the kinetics of stem cell enrichment in a total of 34 standardized LVL for patients with hematologic malignancies (lymphoma, multiple myeloma) and solid tumors (breast cancer, rhabdomyosarcoma). LVL was started 2 h after administration of G-CSF processing six times the patient's blood volume. Cells were sequentially collected into six bags and the numbers of leukocytes, mononuclear cells (MNC), CD34
Several studies have demonstrated the efficacy of large volume leukapheresis (LVL) to collect high yields of peripheral blood progenitor cells (PBPC) for autologous and allogeneic stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] Moreover, a high efficacy of LVL could be confirmed for pediatric patients, [10] [11] [12] [13] although this procedure may be critical for very small patients. 14 However, the mechanisms of stem cell release into the circulation and the kinetics of PBPC enrichment during LVL are not well known. A recruitment phenomenon (an above average increasing number of PBPC harvested during LVL and induced by the LVL) has been postulated in healthy donors and chemotherapymobilized patients. 7, 8, 15 The recruitment of stem cells has been described as a phenomenon, whereby the leukapheresis procedure itself exerts a stimulatory effect on the release of CD34 ϩ cells into the circulation. 16 Recent studies with slightly different regimens in adults gave controversial results. 17, 18 Moreover, recruitment of stem cells during LVL was demonstrated in older but not in younger pediatric patients. 19 Finally, a recent study showed different kinetics of PBPC collections during LVL between adults and pediatric patients without increasing time-dependent collection efficiencies for the pediatric patients. 20 However, the hypothesis of recruitment of progenitor cells caused by LVL has never been proved by comparison with a control group. Accordingly, such a recruitment could not finally be demonstrated in humans treated with G-CSF.
The administration of different chemotherapies and/or cytokines results in individual patterns in the magnitude and course of stem cell mobilization. [21] [22] [23] Moreover, studies in animal models demonstrated large circadian changes of G-CSF blood levels with a maximum of 4 h after administration. 24 Similar pharmacokinetics were found after steadystate mobilization with G-CSF in patients with the highest blood concentrations of G-CSF and PBPC between 2 and 8 h after administration of G-CSF. 25 These data emphasize the necessity of an optimal timing of G-CSF administration.
Finally, different results on potential recruitment in former studies may be explained by individual apheresis procedures. The apheresis processing volumes often have not been adapted to the patients' blood volumes (PBV) and results from adults and pediatric patients may therefore not be comparable. 26, 27 Comparing the former studies with each other, a considerable variability in the processed blood volumes and the point of time of G-CSF administration can be observed. In addition, none of these studies included control groups.
In order to minimize the influence of these individual treatment and collection regimens, this study investigates the kinetics of PBPC enrichment during LVL after stan-dardized administration of G-CSF and with defined blood processing volumes in four different groups of patients.
Materials and methods

Groups of patients
Four groups of patients were defined, comprising patients with hematologic malignancies (patients with lymphoma and multiple myeloma) and with solid tumors (patients with breast cancer and rhabdomyosarcoma). All patients were candidates for autologous high-dose chemotherapy. The clinical status of the patients and the therapy regimens for the different groups are listed in Table 1 .
A total of 34 LVL was performed for 24 adult patients (17-68 years, 42-95 kg). The subgroups comprised 13 LVL in patients with lymphoma, nine LVL in patients with multiple myeloma, eight LVL in patients with breast cancer and four LVL in patients with rhabdomyosarcoma. The monitoring of CD34 ϩ cells in blood was performed daily after mobilizing chemotherapy and administration of G-CSF (10 g G-CSF/kg body weight) when the leukocytes exceeded 500/l blood. A minimum of 50 ϫ 10 3 platelets/l and a hemoglobin of at least 9 g/dl was required for each leukapheresis. All patients received central venous catheter access (Sheldon catheter) prior to the apheresis.
A control group (nine cases) was generated with comparable patients who were mobilized for LVL in the same manner, but who could not be collected for technical reasons (eg no capacity for PBPC apheresis). In this group, blood samples were drawn directly before G-CSF administration as well as 2 and 4 h later. 
Large volume leukapheresis
The LVL were started 2.0 (Ϯ0.5) h after administration of G-CSF. All LVL were performed with a COBE-Spectra cell separator (Cobe-Gambro, Martinsried, Germany; MNC program, software version 5.1). The machine was set, primed and programmed following the manufacturer's instructions.
To analyze the time-and volume-dependent kinetics of stem cell enrichment during LVL, the collection bag (WBC set) was replaced by a six-fold collection bag system, which was connected to the collect line by a sterile docking technique. Total processed volumes consisted of six times the patient's original blood volume (PBV) plus the pre-run volume. This pre-run was defined as the time period from the start until optimization of the interface for MNC collection. When the interface and the color of the collect line were optimized, the first collection bag was opened and the following bags were sequentially opened when processing 2ϫ, 3ϫ, 4ϫ, 5ϫ and 6ϫ the PBV. All LVL were performed by the same two operators and parameters were held as constant as possible throughout the procedure. Only the adjustment of the interface was corrected and optimized under visual control, if necessary.
The effect of the ACD-citrate was antagonized by intravenous administration of 0.5 g calcium chloride/10 kg body weight. In addition, 300 IU heparine were added per 100 ml ACD-citrate to enhance the ACD-citrate ratio to 1:16-24 and therefore increase the flow rate with a reduced addition of citrate. Table 2 shows the main apheresis run parameters of LVL for the total group. A mean volume of 27.8 (Ϯ4.9) liter with a mean flow rate of 93.5 (Ϯ20.8) ml was processed 15 Table 2 Large volume leukapheresis parameters (n ϭ 33) in 307 (Ϯ39.4) min. Accordingly, in addition to the prerun volume, the total processed volume in the LVL was a mean of 6.45 Ϯ 0.11-fold patient's blood volume.
Laboratory analysis
A representative aliquot (1 ml) was drawn from each sequential collection bag for laboratory analysis under sterile conditions. The total numbers of leukocytes (WBC), relative numbers of mononuclear cells (MNC), relative and absolute numbers of CD34 ϩ cells and the total numbers of colony-forming units (CFU-GM) were determined in each sequential collection bag and in the final pooled product. Automated blood counts were performed with a Sysmex-K1000 (Sysmex, Kobe, Japan) counter. MNC purity was determined by microscopic differential counts.
Flow cytometric quantitation of CD34 ϩ cells was performed according to the German consensus protocol for determination of CD34 ϩ cells in blood and apheresis products. 28 Briefly, 100 l cell suspension (10 ϫ 10 9 WBC/l) was incubated for 20 min with 20 l FITC-labelled CD45 ϩ antibody (clone ALB12; Immunotech, Marseille, France) and 20 l phycoerythrin-labelled CD34 ϩ antibody (clone 8G12; Becton Dickinson, San Jose, CA, USA), respectively. Erythrocytes were lysed by a non-fixative lysing reagent (Ortho-mune; Ortho-Diagnostics, Neckargemuend, Germany) and 50 000 (CD45-positive) leukocytes were counted and evaluated.
Short-term culture assays (CFU-GM) were performed as previously described, 29 using the culture medium Methocult H-4433 (Stem Cell Technologies, Vancouver, Canada). 1 ϫ 10 5 nucleated cells were cultured per ml medium and dishes were analyzed (four-fold determinations each) after 14 days of incubation.
Collection efficiency
The collection efficiencies for CD34 ϩ cells of the subsequent collected bags were calculated according to the following formula as previously described: 30 Collection efficiency ϭ (absolute CD34 ϩ cell number of apheresis component) ϫ 100/((pre-apheresis CD34 blood cell count Bone Marrow Transplantation ϩ post-apheresis CD34 blood cell count)/2) ϫ (processed blood volume).
Statistical analysis
Descriptive statistical analysis was performed for the sequentially collected cells (WBC, MNC, CD34 ϩ cells and CFU-GM). Data are shown as mean numbers Ϯ standard deviations. The results for these parameters in the single bags were statistically compared by the Friedman test for non-parametric samples with a level of significance of P Ͻ 0.05. This analysis was performed for the total group as well as for the single subgroups.
For a better clarity and comparability, relative yields instead of absolute yields of PBPC are shown for the sequentially collected bags in the tables. The relative yield is defined as yield of the single bag in relation to the total yield during LVL (ϭ 100%). Table 3 demonstrates the mean numbers of WBC, the percentage of MNC, the numbers of CD34 ϩ cells and CFU-GM and the collection efficiencies for the sequentially collected bags as well as for the final product. These data derive from a total of 34 aphereses from 24 patients. In order to give a better overview of collected clinical doses, the numbers of collected PBPC were converted to CD34 ϩ cells ϫ10 6 /kg bw and CFU ϫ10 4 /kg bw. The mean number of WBC significantly increased at the beginning of the apheresis from 230 to 303 ϫ 10 12 WBC/l during the second processed blood volume (P ϭ 0.001).
Results
The following changes to finally 266 ϫ 10 12 WBC/l were not significant. Accordingly, the collection efficiency of leukocytes was highest during the second processed blood volume, but remained on similar levels throughout the entire apheresis procedures.
The mean relative numbers of MNC in the sequential bags decreased from initially 89% to 84.3% MNC at the end of the apheresis procedure (see Table 3 ). The decrease in purity of MNC became significant after processing four times the patients' blood volumes (P ϭ 0.04).
The 34 LVL resulted in a mean total yield of 7.93 Ϯ 8.2 ϫ 10 6 CD34 ϩ cells/kg bw. The large standard deviations demonstrated a high interindividual variability in yields of PBPC caused by different previous therapies, different treatment regimens and by the individual capacity to mobilize progenitor cells into the circulation. Accordingly, the yields of the single bags were divided by the total numbers of each corresponding LVL to calculate the relative timedependent yields.
The collection efficiencies (CE) for CD34 ϩ cells demonstrated time-dependent changes with a range between 67.1% and 91.6%. The increase of CE between the first and the second bag was statistically significant (P ϭ 0.02), whereas the later changes were not. Figure 1 demonstrates the mean relative yields of CD34 ϩ cells during different stages of LVL for the unselected group (n ϭ 34). The kinetics of CD34 ϩ cells showed a short but significant increase at the beginning of LVL with the highest amount during the second processed blood volume (bag 1 vs bag 2, P ϭ 0.002). Thereafter, a significant continuous decrease could be demonstrated until the end of the LVL, as comparing the later yields of CD34 ϩ cells with the maximum in bag 2 (bag 2 vs bag 3: P ϭ 0.016, vs bag 4: P ϭ 0.001, vs bag 5: P ϭ 0.001, vs bag 6: P ϭ 0.001). Figure 2 shows the mean relative yields of CFU-GM for the same group. In general, the kinetics were comparable to the relative yields of CD34 ϩ cells with a maximum during the second processed blood volume and a consecutive decrease. This decrease became significant after the third processed blood volume (bag 2 vs bag 3: NS, vs bag 4: P ϭ 0.024, vs bag 5: 0.09, vs bag 6: P ϭ 0.001) Figure 3 demonstrates the kinetics of CD34 ϩ cells in peripheral blood before and during different stages of the LVL (n ϭ 12). A significant decrease could be shown at the beginning of the LVL during the first processed blood volume (P ϭ 0.001). Comparing each bag with the following, the further changes were not statistically significant. Processed blood volume P = NS P = 0.024 P = 0.009 P = 0.001
CFU-GM Figure 2 Relative yields of CFU-GM cells during different stages of large volume leukapheresis. Levels of statistical significance were calculated comparing the yields of the second processed blood volume with the yields of the first and all following processed blood volumes. The decrease became significant after the third processed blood volume (P ϭ 0.024). Table 4 shows the numbers of CD34 ϩ cells/l blood for the control group of patients. The blood samples were drawn during application of G-CSF and 2 and 4 h later, respectively. A significant increase of CD34 ϩ cells was observed after 4 h (P ϭ 0.020).
To investigate whether the kinetics of stem cell collection during LVL would show individual patterns for the different diseases, the time-dependent yields of progenitor cells were analyzed for each of the above mentioned diagnoses. Table 5a and b demonstrate the mean relative numbers of CD34 ϩ cells and CFU-GM for the patients with lymphoma (n ϭ 13), multiple myeloma (n ϭ 9), breast cancer (n ϭ 8) and rhabdomyosarcoma (n ϭ 4). For the patients with lymphoma, CD34 ϩ cells as well as CFU-GM were highest during the second processed blood volume with a consecutive decrease at the later stages of LVL. The difference became significant for the CD34 ϩ cells after the second processed blood volume with a continuous drop until the end of the LVL (P ϭ 0.002), whereas the decrease 
Samples were drawn during application of G-CSF as well as 2 and 4 h thereafter. The difference was statistically significant after 4 h.
of CFU-GM did not reach statistical significance. For the patients with multiple myeloma, again, the CD34 ϩ cells and the CFU-GM showed a maximum during the second processed blood volume, followed by a predominantly constant decrease. In this group, the decrease of progenitor cells could be statistically confirmed by the CFU-GM after the last processed blood volume (P ϭ 0.02), whereas the changes of CD34 ϩ cells did not show significant changes. Also for the patients with breast cancer, CD34 ϩ cells as well as CFU-GM were highest during the second processed blood volume and decreased during the later stages of LVL. This drop became significant after the third processed blood volume for CD34 ϩ cells (P ϭ 0.034) and after the fourth processed blood volume for CFU-GM. The patients with rhabdomyosarcoma showed an increase at the start of LVL during the first processed blood volume (P ϭ 0.046). Thereafter, CD34
ϩ cells decreased only after the fourth processed blood volume, whereas the CFU-GM did not show statistically significant changes during the later stages of LVL.
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Discussion
It was the aim of this study to investigate the kinetics of PBPC enrichment during large-volume leukapheresis (LVL) in a standardized autologous setting. Therefore, the G-CSF was administered 2 h prior to the start of LVL and six times the patients' blood volumes were processed. As far as is known, this is the largest study investigating the kinetics of PBPC enrichment during LVL (34 aphereses) and the first study with standardized blood processing volumes in combination with a defined point of time of G-CSF administration. Furthermore, a control group with comparable patients was established.
Former studies have shown that PBPC could be collected during all stages of LVL, although the time-dependent kinetics of stem cell enrichment during LVL varied considerably. 7, 8, [15] [16] [17] [18] [19] [20] Therefore, the standardization of processed blood volumes seems to be necessary to enable a better interindividual comparison. 26, 27 Moreover, animal studies showed distinct changes of G-CSF blood levels and suggest the G-CSF administration 2 h before the start of LVL. 24 A study with steady-state mobilized patients confirmed the time-dependent increase of G-CSF serum levels and CD34
ϩ cells 2 h after administration of cytokines with a maximum after 4 h. 25 Our results show a significant increase of progenitor cells only at the very beginning of the LVL during the first processed blood volume. Thereafter, the harvested PBPC continuously decreased in all groups, as demonstrated by the kinetics of the CD34 ϩ cells or the CFU-GM. Accordingly, the combination of flow cytometric analysis of CD34 ϩ cells and the use of clonogenic growth assays (CFU-GM) was helpful to investigate the kinetics of progenitor cell enrichment during LVL. The continuous decrease of PBPC during the later stages of LVL could be demonstrated for all entities by the combination of both techniques, whereas a decrease for three of the four defined subgroups could only be shown either by determination of CD34 ϩ cells or by counting of CFU-GM. Even for the smallest group of patients with rhabdomyosarcoma, a significant decrease of PBPC yields during LVL was demonstrated. However, a final conclusion about the kinetics of progenitor cells in the latter group should not be drawn, since the number of patients (n ϭ 2) and aphereses (n ϭ 4) in this group was limited. In another earlier study, we processed four times the patients' blood volumes in a smaller and more heterogenous group of patients and found similar changes in yields of CD34 ϩ cells and CFU-GM during LVL. 31 Our data do not support the hypothesis of a recruitment phenomenon of progenitor cells during the LVL in terms of an additional leukapheresis-induced release of PBPC into the peripheral circulation, 19 since a so-called 'recruitment' of PBPC was also observed in the control group. The initial combined increase of PBPC and WBC during the very beginning of the LVL may be caused by a dilution effect in the first bag, probably induced by the filling of the collection line with sodium chloride. This filling is part of the obligatory automated pre-fill procedure of the cell separator and could therefore not be prevented. A dilution effect may be concluded, since the amount of WBC was lowest only in the first bag and showed higher levels in all following
Bone Marrow Transplantation bags without significant changes. This presumption is supported by the fact that the kinetics of the collection efficiencies (CE) and the WBC were similar during different stages of LVL. The calculated results for the CE (mean of 84.4%) were comparable to other studies who used the same cell separator, but partially different software versions for autologous PBPC collections. 30, [32] [33] [34] The recruitment of stem cells has been described as a phenomenon whereby the leukapheresis procedure itself exerts a stimulatory effect on the release of CD34 ϩ cells into the circulation. 16 Hillyer et al 7 first postulated a recruitment of PBPC during LVL in normal donors resulting in a more than two-fold increase of CFU-GM. The hypothesis of recruitment during LVL was supported by following studies. 8, 15, 26 An early study in animals did not support the hypothesis that the LVL itself may induce an additional release of PBPC during the apheresis. 35 Studies with pediatric patients created controversial results demonstrating either no recruitment or recruitment that was shown only in the group of older pediatric patients. 19, 20 Other studies with different regimens demonstrated more or less similar amounts of harvested PBPC during LVL, which resulted in an increase of total yields but did not show a real recruitment of stem cells. 17, 18 However, recruitment of PBPC by LVL may not be postulated if the total yields of PBPC in LVL products are higher than the difference of circulating CD34 ϩ cells before and after LVL. As shown by the results of our control group, this surplus of stem cells may also be explained by a 'recruitment' of stem cells caused by the administration of G-CSF and may not be induced by the LVL itself. The decreasing numbers of CD34 ϩ cells in the peripheral blood of patients with LVL and the increase of CD34 ϩ cells in patients without LVL indicate that the apheresis removes relevant numbers of PBPC from the blood. At least, the chemotherapy and/or cytokines induce a continual release of progenitor cells into peripheral blood (and possibly their return to the marrow). Therefore, it is possible that the apheresis does not have any effect on this release.
A potential recruitment of stem cells, thus an additional release of progenitor cells into circulation induced by the LVL itself, could only be proved or disproved with larger control groups of patients (with identical pretreatment but without LVL). So far, such studies have not been performed. Our results from a large group of patients with standardized G-CSF administration and defined processing volumes do not indicate that a mechanism other than the pharmacodynamic changes of CD34 ϩ cells in blood after administration of G-CSF is responsible for the changes of PBPC yields during LVL. Nonetheless, LVL remains a very efficient method to collect the highest numbers of PBPC with a minimum number of aphereses especially in poorly mobilizing patients. 36 
